<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097747</url>
  </required_header>
  <id_info>
    <org_study_id>AFX01-0401</org_study_id>
    <secondary_id>2004-001655-11</secondary_id>
    <nct_id>NCT00097747</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Double-blind, Placebo-controlled, Dose Escalation Study of the Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affymax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affymax</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum
      pharmacologically active dose of peginesatide in Healthy Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 1, double-blind, placebo-controlled trial of peginesatide, an erythropoiesis
      stimulating agent, with approximately 7 treatment cohorts and 7 healthy volunteer
      participants per cohort. In each cohort of 7 participants, a ratio of 5:2 participants was
      randomly assigned to receive a single dose of peginesatide or placebo, respectively,
      administered as an intravenous infusion. Planned peginesatide dose levels were to escalate by
      cohort. The study was conducted at a single clinical center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) parameters</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Anemia</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Chronic Renal Failure</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single injection administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginesatide 0.025 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginesatide 0.05 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single peginesatide dose of 0.05 mg/kg administered intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginesatide 0.10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single peginesatide dose of 0.10 mg/kg administered intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginesatide</intervention_name>
    <arm_group_label>Peginesatide 0.025 mg/kg</arm_group_label>
    <arm_group_label>Peginesatide 0.05 mg/kg</arm_group_label>
    <arm_group_label>Peginesatide 0.10 mg/kg</arm_group_label>
    <other_name>Omontys</other_name>
    <other_name>Hematide</other_name>
    <other_name>AF37702 Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main eligibility criteria:

          -  Participant is a healthy male, age ≥ 18 years and ≤ 40 years, with body mass index
             (BMI) ≥ 18 and ≤ 30 kilograms per squared meter (kg/m^2), and weight ≥ 50 and ≤ 95
             kilograms (kg)

          -  Participant has hemoglobin of ≤ 16 grams per deciliter (g/dL) at the time of study
             entry

          -  Participant has normal iron stores
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Affymax</last_name>
    <role>Study Director</role>
    <affiliation>Affymax, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>London</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2004</study_first_submitted>
  <study_first_submitted_qc>November 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2004</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>CKD</keyword>
  <keyword>chronic renal failure</keyword>
  <keyword>CRF</keyword>
  <keyword>erythropoietin</keyword>
  <keyword>EPO</keyword>
  <keyword>erythropoiesis stimulating agent</keyword>
  <keyword>ESA</keyword>
  <keyword>Hematide™</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>Hb</keyword>
  <keyword>Hgb</keyword>
  <keyword>Omontys</keyword>
  <keyword>peginesatide</keyword>
  <keyword>red blood cell</keyword>
  <keyword>red blood cell production</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

